Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

Pfizer › Pfizer (NYSE: PFE) has been a terrible investment over the past three years. Revenue and earnings have generally moved in the wrong direction, as the company has been unable to follow up on ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.

Shares in the data-software company were up 7.8% Tuesday after it posted higher quarterly results and [boosted its annual ...

Wondering how well you'd have done if you'd invested in pharmaceutical giant Pfizer (PFE 0.06%) three years ago and hung on?

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

Pfizer raised its full-year profit forecast on Tuesday after topping Wall Street expectations for second-quarter results as ...

Counterfeit Medicine is a growing global threat. At Pfizer, a dedicated team is leading the fight to stop these dangerous ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

Pfizer introduces its next-gen 20-valent pneumococcal conjugate vaccine (PCV20) in India for adult immunization against 20 ...

Pfizer (PFE) recently announced that the U.S. Food and Drug Administration accepted the New Drug Application for ...